The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optimizing the timing of eribulin monotherapy for patients with metastatic breast cancer.
 
Sumito Shingaki
No Relationships to Disclose
 
Takahiro Kogawa
Speakers' Bureau - AstraZeneca Japan; Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo
 
Mototsugu Shimokawa
Consulting or Advisory Role - Sysmex
 
Yumi Fujimoto
Speakers' Bureau - Chugai Pharma
 
Kenichi Harano
No Relationships to Disclose
 
Yoichi Naito
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Eisai; Lilly; Meiji Seika Kaisha; Novartis; Roche; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; Lilly; Merck Serono; Nippon Kayaku
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Reiko Matsui
Speakers' Bureau - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Churchill Pharmaceuticals; Meiji Seika Kaisha; Merck Serono; Nippon Kayaku; Nipro Corporation; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
 
Ako Hosono
Speakers' Bureau - Eisai
Research Funding - Taiho Pharmaceutical
 
Hirofumi Mukai
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca Japan; Daiichi Sankyo; Eisai; GlaxoSmithKline K.K.; Kowa; Lilly Japan; MSD K.K; Novartis; Ono Pharmaceutical; PAREXEL; Pfizer
 
Toru Mukohara
Speakers' Bureau - AstraZeneca Japan; Eisai; Kyowa Hakko Kirin; Novartis